Total Payments
$304,619
2024 Payments
$53,332
Companies
23
Transactions
276
Medicare Patients
166
Medicare Billing
$12,208
Payment Breakdown by Category
Consulting$140,309 (46.1%)
Other$116,595 (38.3%)
Travel$20,924 (6.9%)
Research$20,012 (6.6%)
Food & Beverage$6,591 (2.2%)
Gifts$98.00 (0.0%)
Education$89.99 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $140,309 | 35 | 46.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $110,536 | 29 | 36.3% |
| Travel and Lodging | $20,924 | 71 | 6.9% |
| Unspecified | $20,012 | 24 | 6.6% |
| Food and Beverage | $6,591 | 113 | 2.2% |
| Honoraria | $6,059 | 2 | 2.0% |
| Gift | $98.00 | 1 | 0.0% |
| Education | $89.99 | 1 | 0.0% |
Payments by Type
General
$284,606
252 transactions
Research
$20,012
24 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Blue Earth Diagnostics Limited | $81,879 | 34 | $0 (2024) |
| Lilly USA, LLC | $77,095 | 105 | $0 (2024) |
| GE HEALTHCARE | $55,277 | 23 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $17,540 | 10 | $0 (2024) |
| United Imaging Healthcare North America, Inc. | $13,500 | 3 | $0 (2024) |
| Telix Pharmaceuticals | $13,410 | 20 | $0 (2024) |
| Merck Sharp & Dohme LLC | $9,872 | 12 | $0 (2024) |
| Eli Lilly and Company | $9,297 | 6 | $0 (2023) |
| F. Hoffmann-La Roche AG | $7,808 | 17 | $0 (2018) |
| Eisai Inc. | $7,458 | 7 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $53,332 | 47 | United Imaging Healthcare North America, Inc. ($13,500) |
| 2023 | $48,611 | 34 | Blue Earth Diagnostics Limited ($25,406) |
| 2022 | $22,313 | 8 | GE HealthCare ($22,135) |
| 2021 | $65,493 | 20 | Blue Earth Diagnostics Limited ($48,262) |
| 2020 | $7,654 | 12 | Eisai Inc. ($7,458) |
| 2019 | $24,498 | 21 | GE HEALTHCARE ($17,111) |
| 2018 | $3,499 | 18 | F. Hoffmann-La Roche AG ($3,176) |
| 2017 | $79,220 | 116 | Lilly USA, LLC ($66,085) |
All Payment Transactions
276 individual payment records from CMS Open Payments — Page 1 of 12
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/13/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | — | Cash or cash equivalent | $4,337.00 | Research |
| Study: Research Publication/ Writing Support • Category: Oncology | ||||||
| 11/21/2024 | Blue Earth Diagnostics Limited | POSLUMA (Drug) | Consulting Fee | Cash or cash equivalent | $2,600.00 | General |
| Category: Diagnostic Imaging | ||||||
| 11/05/2024 | Siemens Medical Solutions USA, Inc. | Biograph mCT X-4R (Device) | Food and Beverage | In-kind items and services | $17.57 | General |
| Category: MI - Nuclear Medicine (incl. PETNET & MIBR) | ||||||
| 10/10/2024 | Novartis Pharmaceuticals Corporation | — | Consulting Fee | Cash or cash equivalent | $2,625.00 | General |
| 10/03/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | Cash or cash equivalent | $72.00 | General |
| 10/01/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $6,710.00 | General |
| 10/01/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $88.04 | General |
| 10/01/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | Cash or cash equivalent | $49.15 | General |
| 09/21/2024 | Telix Pharmaceuticals | ILLUCCIX (Drug) | Food and Beverage | In-kind items and services | $105.09 | General |
| Category: PROSTATE CANCER DIAGNOSIS | ||||||
| 09/21/2024 | Telix Pharmaceuticals | ILLUCCIX (Drug) | Food and Beverage | In-kind items and services | $102.41 | General |
| Category: PROSTATE CANCER DIAGNOSIS | ||||||
| 09/21/2024 | Telix Pharmaceuticals | ILLUCCIX (Drug) | Food and Beverage | In-kind items and services | $72.58 | General |
| Category: PROSTATE CANCER DIAGNOSIS | ||||||
| 09/20/2024 | Telix Pharmaceuticals | ILLUCCIX (Drug) | Travel and Lodging | Cash or cash equivalent | $597.95 | General |
| Category: PROSTATE CANCER DIAGNOSIS | ||||||
| 09/20/2024 | Telix Pharmaceuticals | ILLUCCIX (Drug) | Travel and Lodging | Cash or cash equivalent | $398.51 | General |
| Category: PROSTATE CANCER DIAGNOSIS | ||||||
| 09/20/2024 | Telix Pharmaceuticals | ILLUCCIX (Drug) | Food and Beverage | In-kind items and services | $169.42 | General |
| Category: PROSTATE CANCER DIAGNOSIS | ||||||
| 09/13/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $65.00 | General |
| 09/13/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $60.80 | General |
| 09/13/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $54.95 | General |
| 09/12/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $2,034.57 | General |
| 09/12/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $249.00 | General |
| 09/12/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $169.36 | General |
| 09/12/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $169.36 | General |
| 09/12/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $149.95 | General |
| 08/19/2024 | Telix Pharmaceuticals | ILLUCCIX (Drug), ILLUCCIX | Food and Beverage | In-kind items and services | $166.57 | General |
| Category: PROSTATE CANCER THERAPY | ||||||
| 08/01/2024 | Blue Earth Diagnostics Limited | POSLUMA (Drug) | Consulting Fee | Cash or cash equivalent | $325.00 | General |
| Category: Diagnostic Imaging | ||||||
| 07/10/2024 | Blue Earth Diagnostics Limited | POSLUMA (Drug) | Consulting Fee | Cash or cash equivalent | $3,250.00 | General |
| Category: Diagnostic Imaging | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY AND SAFETY STUDY OF CRENEZUMAB IN PATIENTS WITH PRODROMAL TO MILD ALZHEIMER'S DISEASE | F. Hoffmann-La Roche AG | $5,212 | 10 |
| Research Publication/ Writing Support | Novartis Pharmaceuticals Corporation | $4,337 | 1 |
| A 24-MONTH, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY, SAFETY, TOLERABILITY, BIOMARKER, AND PHARMACOKINETIC STUDY OF AZD3293 IN EARLY ALZHEIMERS DISEASE -THE AMARANTH STUDY | Eli Lilly and Company | $3,825 | 1 |
| A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY AND SAFETY STUDY OF CRENEZUMAB IN PATIENTS WITH PRODROMAL TO MILD ALZHEIMERS DISEASE | F. Hoffmann-La Roche AG | $1,789 | 3 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED AND DELAYED-START STUDY OF LY3314814 IN MILD ALZHEIMERS DISEASE DEMENTIA | Eli Lilly and Company | $1,538 | 1 |
| AN OPEN LABEL, MULTICENTER STUDY, EVALUATING THE IMAGING CHARACTERISTICS OF A FOLLOW-UP 18F-AV-1451 SCAN IN SUBJECTS WHO HAVE HAD A PRIOR 18F-AV-1451 SCAN | Avid Radiopharmaceuticals, Inc. | $1,271 | 1 |
| A STUDY OF LY3202626 ON DISEASE PROGRESSION IN PARTICIPANTS WITH MILD ALZHEIMERS DISEASE DEMENTIA | Eli Lilly and Company | $903.58 | 1 |
| A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE- BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY AND SAFETY STUDY OF CRENEZUMAB IN PATIENTS WITH MILD ALZHEIMER'S DISEASE | F. Hoffmann-La Roche AG | $446.55 | 1 |
| A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE- BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY AND SAFETY STUDY OF CRENEZUMAB IN PATIENTS WITH MILD ALZHEIMERS DISEASE | F. Hoffmann-La Roche AG | $315.54 | 2 |
| A 24-MONTH, PHASE 3, MULTICENTER, PLACEBO-CONTROLLED STUDY OF EFFICACY AND SAFETY OF SOLANEZUMAB VERSUS PLACEBO IN PRODROMAL ALZHEIMERS DISEASE | Eli Lilly and Company | $269.99 | 1 |
| A SINGLE- AND MULTIPLE-DOSE STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SINGLE AND MULTIPLE INTRAVENOUS DOSES OF LY3002813 IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT DUE TO ALZHEIMERS DISEASE OR MILD TO MODERATE ALZHEIMERS DISEASE OR MILD TO MODERATE ALZHEIMERS DISEASE | Eli Lilly and Company | $59.68 | 1 |
| CHECK A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY AND SAFETY STUDY OF CRENEZUMAB IN PATIENTS WITH PRODROMAL TO MILD ALZHEIMERS DISEASE | F. Hoffmann-La Roche AG | $44.53 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2020 | 4 | 166 | 170 | $44,978 | $12,208 |
Total Patients
166
Total Services
170
Medicare Billing
$12,208
Procedure Codes
5
All Medicare Procedures & Services
5 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 78815 | Nuclear medicine study with ct imaging skull base to mid-thigh | Office | 2020 | 89 | 90 | $27,450 | $7,182 | 26.2% |
| 78816 | Nuclear medicine study with ct imaging whole body | Office | 2020 | 29 | 32 | $9,824 | $2,635 | 26.8% |
| 78452 | Nuclear medicine study of vessels of heart using drugs or exercise multiple studies | Facility | 2020 | 18 | 18 | $3,654 | $1,129 | 30.9% |
| 78803 | Spect nuclear medicine localization of tumor or inflammation or study of distribution of radioactive tracer in single area, 1 day of imaging | Facility | 2020 | 19 | 19 | $2,565 | $798.48 | 31.1% |
| 78803 | Spect nuclear medicine localization of tumor or inflammation or study of distribution of radioactive tracer in single area, 1 day of imaging | Office | 2020 | 11 | 11 | $1,485 | $464.36 | 31.3% |
About Phillip Kuo, M.D. PH.D
Phillip Kuo, M.D. PH.D is a Nuclear Radiology healthcare provider based in Duarte, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/30/2008. The National Provider Identifier (NPI) number assigned to this provider is 1336315316.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Phillip Kuo, M.D. PH.D has received a total of $304,619 in payments from pharmaceutical and medical device companies, with $53,332 received in 2024. These payments were reported across 276 transactions from 23 companies. The most common payment nature is "Consulting Fee" ($140,309).
As a Medicare-enrolled provider, Kuo has provided services to 166 Medicare beneficiaries, totaling 170 services with total Medicare billing of $12,208. Data is available for 1 year (2020–2020), covering 5 distinct procedure/service records.
Ad
Practice Information
- Specialty Nuclear Radiology
- Other Specialties Diagnostic Radiology, Diagnostic Radiology
- Location Duarte, CA
- Active Since 04/30/2008
- Last Updated 11/19/2024
- Taxonomy Code 2085N0904X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1336315316
Products in Payments
- AMYVID (Drug) $71,967
- POSLUMA (Drug) $30,668
- uMI Panorama GS (Device) $10,200
- Non-Covered Product (Drug) $7,808
- ILLUCCIX (Drug) $5,910
- Nubeqa (Drug) $5,401
- PLUVICTO (Drug) $4,905
- VIZAMYL (Drug) $3,200
- Axumin (Drug) $2,949
- DATSCAN (Drug) $2,405
- uPMR 790 PET (Device) $2,250
- Xofigo (Drug) $1,981
- uMI Panvivo (Device) $1,050
- Urolift - UL400 (Device) $124.98
- Non-Product Specific (Device) $121.70
- Xolair (Biological) $112.18
- ASTRA TECH Implant System (Device) $96.52
- Lymphoseek (Drug) $56.66
- LEXISCAN (Drug) $30.72
- Lexiscan (Drug) $17.82
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.